InVitria Optimizes Hybridoma Cell Culture With New Product Zap-HybridomaFor diagnostic and monoclonal antibody production, Zap-Hybridoma improves target antibody purity and hybridoma productivity  Fort Collins, CO March 2, 2010 -InVitria's launch of Zap-Hybridoma provides a powerful solution for hybridoma cell culture. Zap-Hybridoma was created to improve monoclonal antibody productivity and deliver easier purification of the target product.Zap-Hybridoma was developed by InVitria's Cell Culture Development team as an answer to many of the challenges facing scientists working with hybridoma cell culture. "Not only can Zap-Hybridoma increase productivity, it delivers consistent results and allows hybridoma cells to more quickly adapt away from FBS (fetal bovine serum)," said Dr. Steve Pettit, InVitria's Director of Cell Culture Development. "We tested Zap-Hybridoma in six of the leading commercial hybridoma media on the market today and observed faster cell growth, a 50% average increase in maximum cell density and increased monoclonal antibody yield when compared to the recommended use of the manufacturer." "Zap-Hybridoma is an innovation InVitria is proud to bring to its customers so they can achieve better performance more consistently," said Scott Deeter, InVitria President and CEO. We developed Zap-Hybridoma to give users an IgG free alternative to FBS without sacrificing performance." Zap-Hybridoma vs. FBS
To order your sample of Zap-Hybridoma or to receive more information, please visit Zap-Hybridoma. About InVitria - InVitria.com InVitria specializes in cell culture media optimization for the biotechnology industry. InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics. For more information about InVitria's product solutions, e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311. ###
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
